Published in Cardiovasc Res on January 05, 2006
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
An overview of tissue and whole organ decellularization processes. Biomaterials (2011) 4.78
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell (2009) 4.48
ECM remodeling in hypertensive heart disease. J Clin Invest (2007) 4.03
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol (2009) 3.55
Progress in matrix metalloproteinase research. Mol Aspects Med (2008) 2.51
The impact of the extracellular matrix on inflammation. Nat Rev Immunol (2010) 2.30
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.07
Mechanotransduction and extracellular matrix homeostasis. Nat Rev Mol Cell Biol (2014) 1.94
Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis (2008) 1.82
Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol (2013) 1.77
Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest (2010) 1.75
Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta (2011) 1.73
Single-molecule tracking of collagenase on native type I collagen fibrils reveals degradation mechanism. Curr Biol (2012) 1.63
Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep (2011) 1.62
Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer (2009) 1.58
Mechanisms of arterial remodeling in hypertension: coupled roles of wall shear and intramural stress. Hypertension (2008) 1.52
Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res (2011) 1.45
Direct visualization of protease activity on cells migrating in three-dimensions. Matrix Biol (2008) 1.42
Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda) (2013) 1.41
How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther (2007) 1.40
Pathogenesis of tendinopathies: inflammation or degeneration? Arthritis Res Ther (2009) 1.39
Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol (2008) 1.37
Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J Biol Chem (2009) 1.37
Protease-activated drug development. Theranostics (2012) 1.36
Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med (2007) 1.32
Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J (2008) 1.32
Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes. Arthritis Res Ther (2007) 1.32
Molecular mechanism of type I collagen homotrimer resistance to mammalian collagenases. J Biol Chem (2010) 1.30
Angiogenesis in melanoma. Semin Oncol (2007) 1.30
Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine (2008) 1.30
Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am J Respir Crit Care Med (2014) 1.29
Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int (2010) 1.29
Matrix metalloproteinase 9 (MMP9) expression in preeclamptic decidua and MMP9 induction by tumor necrosis factor alpha and interleukin 1 beta in human first trimester decidual cells. Biol Reprod (2008) 1.28
Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. Cancer Res (2010) 1.26
Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost (2009) 1.24
Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun (2007) 1.23
Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Dev Biol (2007) 1.23
Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta (2009) 1.23
Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther (2013) 1.21
The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair (2014) 1.19
Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br J Pharmacol (2009) 1.18
The MMP-9/TIMP-1 axis controls the status of differentiation and function of myelin-forming Schwann cells in nerve regeneration. PLoS One (2012) 1.18
Matrix metalloproteinase expression levels suggest distinct enzyme roles during lumbar disc herniation and degeneration. Eur Spine J (2009) 1.17
Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer (2008) 1.17
Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL. Brain (2013) 1.16
Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics. Acta Orthop (2009) 1.16
Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. Am J Physiol Lung Cell Mol Physiol (2010) 1.15
Rac1-mediated mitochondrial H2O2 generation regulates MMP-9 gene expression in macrophages via inhibition of SP-1 and AP-1. J Biol Chem (2010) 1.14
Expression and regulation of metalloproteinases and their inhibitors in intervertebral disc aging and degeneration. Spine J (2013) 1.13
Carbodiimide cross-linking inactivates soluble and matrix-bound MMPs, in vitro. J Dent Res (2011) 1.12
Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med (2012) 1.12
Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol (2010) 1.11
Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 1.11
Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol (2012) 1.11
Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2011) 1.10
Acute endotoxin-induced thymic atrophy is characterized by intrathymic inflammatory and wound healing responses. PLoS One (2011) 1.10
Critical role of transient activity of MT1-MMP for ECM degradation in invadopodia. PLoS Comput Biol (2013) 1.07
Gelatin in situ zymography on fixed, paraffin-embedded tissue: zinc and ethanol fixation preserve enzyme activity. J Histochem Cytochem (2009) 1.07
Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim Biophys Acta (2007) 1.07
Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation. J Biol Chem (2007) 1.06
Matrix metalloproteases and PAR1 activation. Blood (2012) 1.05
MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer (2011) 1.04
Elevated MMP Expression in the MRL Mouse Retina Creates a Permissive Environment for Retinal Regeneration. Invest Ophthalmol Vis Sci (2008) 1.04
The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesis. J Biol Chem (2010) 1.04
Lymphocyte/macrophage interactions: biomaterial surface-dependent cytokine, chemokine, and matrix protein production. J Biomed Mater Res A (2008) 1.03
Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS (2012) 1.03
Diffusion of MMPs on the surface of collagen fibrils: the mobile cell surface-collagen substratum interface. PLoS One (2011) 1.03
Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-κB. PLoS One (2012) 1.03
Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J (2010) 1.03
Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: Potential implications in varicose veins. J Vasc Surg (2008) 1.02
Interdomain flexibility in full-length matrix metalloproteinase-1 (MMP-1). J Biol Chem (2009) 1.02
Acrolein activates matrix metalloproteinases by increasing reactive oxygen species in macrophages. Toxicol Appl Pharmacol (2009) 1.02
Molecular mechanisms and in vivo mouse models of skin aging associated with dermal matrix alterations. Lab Anim Res (2011) 1.02
Hyaluronic acid and thrombin upregulate MT1-MMP through PI3K and Rac-1 signaling and prime the homing-related responses of cord blood hematopoietic stem/progenitor cells. Stem Cells Dev (2010) 1.02
MT1-MMP regulates the turnover and endocytosis of extracellular matrix fibronectin. J Cell Sci (2011) 1.02
The evolution of the vertebrate metzincins; insights from Ciona intestinalis and Danio rerio. BMC Evol Biol (2007) 1.02
Mechanotransduction and cartilage integrity. Ann N Y Acad Sci (2011) 1.02
Resistance to bleomycin-induced lung fibrosis in MMP-8 deficient mice is mediated by interleukin-10. PLoS One (2010) 1.01
Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS One (2012) 1.01
Novel transcriptional profile in wrist muscles from cerebral palsy patients. BMC Med Genomics (2009) 1.01
MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties. J Biol Chem (2007) 1.01
The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes. Stem Cell Rev (2011) 1.01
Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology (2007) 1.00
Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med (2011) 0.99
Matrix metalloproteinase-9 controls proliferation of NG2+ progenitor cells immediately after spinal cord injury. Exp Neurol (2011) 0.99
Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas. Genes Dis (2015) 0.99
Effect of phosphoric acid on the degradation of human dentin matrix. J Dent Res (2012) 0.99
Defining requirements for collagenase cleavage in collagen type III using a bacterial collagen system. J Biol Chem (2012) 0.98
Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res (2015) 0.98
Hydrogen sulfide mitigates matrix metalloproteinase-9 activity and neurovascular permeability in hyperhomocysteinemic mice. Neurochem Int (2009) 0.98
Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. ScientificWorldJournal (2013) 0.97
Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod (2013) 0.97
Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem (2012) 0.97
The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Des Devel Ther (2014) 0.97
Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion. Circulation (2008) 0.97
The interface between catalytic and hemopexin domains in matrix metalloproteinase-1 conceals a collagen binding exosite. J Biol Chem (2011) 0.97
Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther (2009) 0.97
Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci (2002) 4.23
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med (2003) 3.20
Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J (2004) 2.58
Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell (2006) 2.43
ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci (2005) 1.99
Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J (2010) 1.93
Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res (2005) 1.77
Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci (2002) 1.69
Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci (2003) 1.68
Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem (2005) 1.59
ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun (2002) 1.55
The roles of substrate thermal stability and P2 and P1' subsite identity on matrix metalloproteinase triple-helical peptidase activity and collagen specificity. J Biol Chem (2006) 1.49
Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc Natl Acad Sci U S A (2012) 1.46
Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol (2002) 1.41
Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 1.34
Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem (2003) 1.32
Molecular mechanism of type I collagen homotrimer resistance to mammalian collagenases. J Biol Chem (2010) 1.30
X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding. J Biol Chem (2004) 1.30
Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. Cancer Res (2010) 1.26
Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture. Exp Eye Res (2003) 1.26
Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A (2011) 1.26
Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem (2004) 1.24
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem (2007) 1.22
Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem (2002) 1.22
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol (2008) 1.21
Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol (2009) 1.20
Crystal structure of an active form of human MMP-1. J Mol Biol (2006) 1.20
Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem (2004) 1.18
Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes. Arthritis Res Ther (2011) 1.15
Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol (2005) 1.14
The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett (2002) 1.13
Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli. J Gerontol A Biol Sci Med Sci (2005) 1.13
Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue. Exp Eye Res (2003) 1.13
A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PLoS One (2012) 1.12
Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J Biol Chem (2007) 1.09
Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making. Brain (2012) 1.07
The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry (2010) 1.06
Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res (2006) 1.04
Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases. J Biol Chem (2001) 1.04
Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J Biol Chem (2004) 1.03
The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Lett (2002) 1.02
Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. J Biol Chem (2003) 1.02
Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost (2002) 1.01
Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry (2007) 1.01
Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme. J Biol Chem (2005) 1.01
TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J Biol Chem (2007) 1.01
Family-based investigation of the C677T polymorphism of the methylenetetrahydrofolate reductase gene in ischaemic heart disease. Atherosclerosis (2002) 1.01
Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. Cancer Res (2005) 1.00
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics (2003) 1.00
Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. J Thorac Oncol (2010) 1.00
The dimer interface of the membrane type 1 matrix metalloproteinase hemopexin domain: crystal structure and biological functions. J Biol Chem (2010) 0.99
Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett (2002) 0.99
Defining requirements for collagenase cleavage in collagen type III using a bacterial collagen system. J Biol Chem (2012) 0.98
Human corneal epithelial cells require MMP-1 for HGF-mediated migration on collagen I. Invest Ophthalmol Vis Sci (2003) 0.98
Reactive-site mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5: biological and structural implications. Biochem J (2010) 0.97
Lactoferricin mediates anabolic and anti-catabolic effects in the intervertebral disc. J Cell Physiol (2012) 0.97
MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci (2010) 0.97
Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. Biochem J (2002) 0.96
Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One (2012) 0.95
Differential expression of matrix metalloproteinases during impaired wound healing of the diabetes mouse. J Invest Dermatol (2002) 0.94
Role of the netrin-like domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity. J Biol Chem (2010) 0.93
Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem J (2003) 0.92
Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases. Biochemistry (2004) 0.92
Matrix metalloproteinases at a glance. J Cell Sci (2004) 0.92
Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-alpha-converting enzyme. J Biol Chem (2004) 0.92
ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer (2006) 0.90
Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay. Clin Chem (2002) 0.89
The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Biochem J (2008) 0.89
Photoletter to the editor: Oral ulceration in pyoderma gangrenosum. J Dermatol Case Rep (2011) 0.88
Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. Matrix Biol (2002) 0.88
Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex. Biochem J (2012) 0.87
Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness. J Pathol (2011) 0.87
Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). Biochem J (2010) 0.87
Crystal structure of full-length human collagenase 3 (MMP-13) with peptides in the active site defines exosites in the catalytic domain. FASEB J (2013) 0.87
Membrane type 1 matrix metalloproteinase (MT1-MMP) ubiquitination at Lys581 increases cellular invasion through type I collagen. J Biol Chem (2012) 0.87
Membrane-type 1 matrix metalloproteinase stimulates cell migration through epidermal growth factor receptor transactivation. Mol Cancer Res (2007) 0.87
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg Med Chem (2004) 0.86
Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. Exp Cell Res (2005) 0.85
Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering. Protein Sci (2002) 0.85
Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1. Tumour Biol (2005) 0.85
Granulocyte-macrophage colony stimulating factor induces endothelial capillary formation through induction of membrane-type 1 matrix metalloproteinase expression in vitro. Int J Cancer (2008) 0.84
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg Med Chem (2006) 0.84
The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment. Cancer Lett (2009) 0.84
Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK-1 in HT1080 fibrosarcoma cells. FEBS Lett (2004) 0.84
Endothelial nitric oxide synthase gene polymorphism and ischemic heart disease. Am Heart J (2004) 0.83
Assessment of gelatinase expression and activity in articular cartilage. Methods Mol Med (2007) 0.83
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J Med Chem (2009) 0.83
Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol (2006) 0.83
LPS activates ADAM9 dependent shedding of ACE from endothelial cells. Biochem Biophys Res Commun (2012) 0.82
Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res (2011) 0.82
Modulation of integrin α4β1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration. Cell Biol Int (2011) 0.82
The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths. Hum Pathol (2006) 0.82
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization. Eur J Med Chem (2011) 0.81
Investigation of the role of Endo180/urokinase-type plasminogen activator receptor-associated protein as a collagenase 3 (matrix metalloproteinase 13) receptor. Biochem J (2002) 0.81
MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells. Biochem J (2006) 0.81
Golgi reassembly stacking protein 55 interacts with membrane-type (MT) 1-matrix metalloprotease (MMP) and furin and plays a role in the activation of the MT1-MMP zymogen. FEBS J (2010) 0.80
Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice. PLoS One (2013) 0.80